Dr. Larry Lynd is a Professor in the University of British Columbia (UBC) Faculty of Pharmaceutical Sciences, Scientist at the Centre for Health Evaluation and Outcome Sciences (CHÉOS), and the Director of the Collaboration for Outcomes Research and Evaluation (CORE). Additionally, he is an Associate of the UBC School of Population and Public Health, and a Scholar at the Peter Wall Institute for Advanced Studies at UBC. Formerly, he was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research (CIHR) New Investigator.
Dr. Lynd has more than 200 peer-reviewed publications, book chapters, and research abstracts. He currently sits as the economics expert on the the B.C. Ministry of Health Services Expensive Drugs for Rare Diseases Advsiory Committee. His primary research interests are in the areas of risk-benefit analysis, pharmacoepidemiology, health economics, and policy making for drugs for rare diseases. He is the principal investigator on the CIHR New Emerging Team for Rare Diseases, focused on policy and decision-making for orphan drugs.